LYFE Capital
64
51M
48
6.40
13
0.25
2
- Stages of investment
- Areas of investment
Summary
The venture was found in Asia in China. The main office of represented VC is situated in the Shanghai.
Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Ansun BioPharma, Burning Rock Biotech, Aohua The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Therapeutics, Biotechnology.
The current fund was established by Drake Yu, James Zhao.
The usual cause for the fund is to invest in rounds with 5 partakers. Despite the LYFE Capital, startups are often financed by Legend Star, Sequoia Capital China, Nest.Bio Ventures. The meaningful sponsors for the fund in investment in the same round are Sequoia Capital China, Legend Star, Viventures. In the next rounds fund is usually obtained by Sequoia Capital China, Lilly Asia Ventures, Legend Star.
Investments analytics
Analytics
- Total investments
- 64
- Lead investments
- 13
- Exits
- 2
- Rounds per year
- 6.40
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (43)
- Health Care (41)
- Medical (16)
- Pharmaceutical (11)
- Therapeutics (11) Show 22 more
- Investments by region
-
- China (46)
- United States (14)
- France (2)
- Israel (1)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 24M
- Group Appearance index
- 0.97
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Levostar | 11 Apr 2022 | Health Care, Health Diagnostics, Medical | Seed | Jiangsu, Suzhou, China | |
| neoX Biotech | 08 Jul 2021 | Biotechnology, Artificial Intelligence, Health Care, Product Research | Early Stage Venture | Beijing, Beijing, China |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.